Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
Where this comes from
- Record sourced from PubMed, PMID 21926167.
- Also identified by DOI 10.1158/1078-0432.CCR-11-1768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is variable in mRCC, but changes in FDG-PET uptake may be useful in monitoring disease progression. Further work is needed to personalize treatment for patients with mRCC.
Medical subject headings
- Carcinoma, Renal Cell
- Fluorodeoxyglucose F18
- Kidney Neoplasms
- Positron-Emission Tomography
- Radiopharmaceuticals